Why I’m NOT Buying Intuitive Surgical
1 extracted signal · 1 resolved · 0 still active
Christophe Nour - The French InvestorIndependent analyst profile- Source published
- 27 Jul 2026, 14:45 UTC
- Recorded by Tahlil Plus
- 02 Aug 2026, 11:50 UTC
AI-generated source summary
The analysis suggests that ISRG is currently undervalued with a projected CAGR of 12.36% from its current share price. The target buy price is estimated at $375.25 to achieve a desired return of 10%. The company's financial performance has been solid with strong revenue growth and high margins. The current stock price is $337.50. A key concern for investors is the increasing competition and regulatory environment in China, which might impact the company's market share. However, the company's own robotic surgery technology and expansion into new markets are seen as positive drivers. The valuation appears reasonable considering the growth potential and market position, but the current P/E ratio of 30 suggests it is not a deep value play. Given the company's strong financial health, solid growth, and market leadership, it remains an attractive stock for long-term investors. The analysis suggests that a 10% return could be achieved if the price reaches $603.94 based on future stock price projections. However, the fair value is estimated at $297.05, indicating it is currently overvalued. The analysis indicates that a price-to-earnings ratio of 25 is a more reasonable valuation point.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Christophe Nour - The French Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.